Therefore, Romidepsin can not only serve as a drug for the treatment of GBM, but also as a potential R-loop structure agonist in GSCs to antagonize YTHDC1-mediated circPOLR2B efflux from the nucleus. This evidence concerns the gene YTHDC1 and glioblastoma.